The Johns Hopkins School of Medicine, Baltimore, MD, USA.
Department of Medicine, Johns Hopkins Hospital, Baltimore, MD, USA.
Adv Exp Med Biol. 2021;1318:499-515. doi: 10.1007/978-3-030-63761-3_29.
Coronavirus disease 2019 (COVID-19) is a highly contagious infectious disease that can rapidly escalate to respiratory failure and death. It has infected millions of people worldwide. The trajectory of this disease continues to progress in some areas of the United States and worldwide. The Institute for Health Metrics now predicts a resurgence of infections in the fall of 2020. The pathogenesis of COVID-19 includes an inflammatory phase with either resolution or the potential to accelerate to a cytokine storm, characterized by high interleukin (IL)-6 and other inflammatory markers. COVID-19 is a condition without a gold-standard treatment. The US Federal Drug Administration (FDA) issued an emergency use authorization for remdesivir in severe cases of COVID-19, which shortened the recovery time in hospitalized patients with lower respiratory tract infection in one study. Although several vaccine trials are underway, no vaccines are available for primary prevention of COVID-19 at this time. Dietary supplement sales have dramatically risen during the COVID-19 pandemic despite depressed economic conditions. Commonly used immune-modulating dietary supplements, including vitamin D, ascorbic acid, zinc, and melatonin, are reviewed in this manuscript highlighting biological plausibility for salutary benefit against COVID-19. Ongoing clinical trials recruiting subjects at the time of this writing are provided for each dietary supplement.
新型冠状病毒病(COVID-19)是一种高传染性的传染病,可迅速发展为呼吸衰竭和死亡。它已经感染了全球数百万人。该疾病的轨迹在美国和全球的某些地区仍在继续发展。健康指标研究所现在预测 2020 年秋季感染会再次出现。COVID-19 的发病机制包括炎症期,要么消退,要么有可能加速发展为细胞因子风暴,其特征是白细胞介素(IL)-6 和其他炎症标志物水平升高。COVID-19 没有标准的治疗方法。美国联邦药物管理局(FDA)发布了瑞德西韦在 COVID-19 重症病例中的紧急使用授权,一项研究表明,该药缩短了住院下呼吸道感染患者的康复时间。尽管经济状况不佳,但在 COVID-19 大流行期间,膳食补充剂的销售额大幅上升。本文综述了常用的免疫调节膳食补充剂,包括维生素 D、抗坏血酸、锌和褪黑素,强调了它们对 COVID-19 有益的生物学可能性。本文还提供了每个膳食补充剂在撰写本文时正在招募受试者的正在进行的临床试验。